Selective Screening for the Factor V Leiden Mutation: Is it Advisable prior to the Prescription of Oral Contraceptives?

Summary

The cumulative thrombotic risk of Factor V (FV) Leiden and oral contraceptives (OC) recommends screening for the mutation. Assuming that a family history of thrombosis increases the patient’s likelihood of bearing FV Leiden, a selective rather than universal screening would be performed. We studied the utility of a family history of thrombosis for screening of FV Leiden before prescription of OC and, furthermore, the utility of screening even if oral contraception is favoured. 101 patients who had their first and single thromboembolic event while using OC were interviewed. 609 women without any history of thromboembolism recruited by gynecologists completed a standard questionnaire. 101 of these women, age-matched and currently using OC, were selected for a case-control study. Regarding patients with previous thromboembolism, a family history in a first-degree relative had a positive predictive value (PPV) of only 14% for FV Leiden. A PPV of 12% was calculated by investigating the 609 thrombosis-free women. Inherited FV Leiden (odds ratio = 4.9) and acquired risk factors (odds ratio = 10.1) were both found to be the most prominent, but independent additional risks. Nevertheless, FV Leiden carriers, both heterozygotes and homozygotes, did not suffer earlier from thromboembolism than patients without the mutation. In conclusion, family history is an unreliable criterion to detect FV Leiden carriers. Screening for factor V Leiden can be worthwhile even if the advantages of oral contraception are higher assessed than the thrombotic risk. Affected women knowing about their additional risk could contribute to the prevention of thrombosis in risk situations.

• References

• 1 WHO collaborative study of cardiovascular disease and steroid hormone contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995; 346: 1575-1582
• 2 WHO collaborative study of cardiovascular disease and steroid hormone contraception. Effect of different progestagens in low oestrogen oral contraceptives on venous thrombosis disease. Lancet 1995; 346: 1582-1588
• 3 Spitzer WO, Lewis MA, Heinemann LAJ, Thorogood M, MacRae KD. Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study. Br Med J 1996; 312: 83-88
• 4 Dahlbcäk B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-1008
• 5 Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, Ronde H de, Velden PAVan der, Reitsma PH. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 369: 64-67
• 6 Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-1457
• 7 Noe DA. The logic of laboratory medicine. München; Urban Schwarzenberg: 1985
• 8 Rosendaal FR. Oral contraceptives and screening for factor V Leiden. Thromb Haemost 1996; 75: 524-525
• 9 Vandenbroucke JP, van der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. Br Med J 1996; 313: 1127-1130
• 10 Widmer LK, Brandenberg E, Schmitt HE, Widmer M-T, Voelin R, Zemp E, Madar G. The fate of patients after deep vein thrombosis. Dtsch Med Wochenschr 1985; 110: 993-997
• 11 Prager M, Huk I, Kretschmer G, Polterauer P. Surgical therapy of acute thrombosis of leg-pelvic veins. Acta Med Austriaca 1994; 21: 102-104
• 12 Eichlisberger R, Widmer MT, Frauchiger B, Widmer LK, Jager K. The incidence of post-thrombotic syndrome. Wien Med Wochenschr 1994; 144: 192-195
• 13 Heijboer H, Brandjes DPM, Büller HR, Sturk A, ten Cate JW. Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. N Engl J Med 1990; 323: 1512-1516
• 14 Pabinger I, Schneider B. and the GTH study group on natural inhibitors. hrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548-552
• 15 Rintelen C, Mannhalter C, Ireland H, Lane DA, Knöbl P, Lechner K, Pabinger I. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for factor V Leiden. Br J Haematol 1996; 93: 487-490
• 16 Bloemenkamp KWM, Rosendaal FR, Helmerhorst FM, Biiller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995; 346: 1593-1596
• 17 Frank-Herrmann P, Freundl G, Baur S, Bremme M, Döring GK, Godehardt EAJ, Sottong U. Effectiveness and acceptability of the symptothermal method of natural family planning in Germany. Am J Obstet Gynecol 165: 2052-2054 1991;
• 18 European Natural Family Planning Study Groups. Prospective european multicentre study of natural family planning: interim results. Adv Contracept 9: 269-283 1993;